News Roswell Park Presents ‘Highly Encouraging’ Phase 2A Results on SurVaxM Immunotherapy for Glioblastoma
News Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM